3:26 PM
 | 
Jul 10, 2018
 |  BC Extra  |  Clinical News

Pilot supports real-world endpoints as surrogates for OS

Friends of Cancer Research released data Tuesday that support the use of real-world evidence (RWE) outcomes -- including real-world progression-free survival (rwPFS) -- as surrogate endpoints for overall survival to evaluate a treatment's long-term effects.

In the pilot program, a working group led by the non-profit Friends evaluated electronic health records (EHR) and claims data from non-small cell lung cancer patients receiving anti-PD-L1 mAb Tecentriq atezolizumab and anti-PD-1 mAbs Opdivo nivolumab and Keytruda pembrolizumab in the postmarket setting. Friends measured the correlation between several real-world endpoints and OS using Spearman’s rank correlation co-efficient, which ranges from 1 when the variables are identical to -1 when they are fully...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >